Literature DB >> 7106172

Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults.

S M Huang, N K Athanikar, K Sridhar, Y C Huang, W L Chiou.   

Abstract

Plasma and urinary levels of chlorpheniramine (CPM) and its 2 demethylated metabolites were measured by HPLC after i.v. and oral dosing. In 5 mg (maleate) i.v. bolus studies in 2 subjects, plasma CPM levels were fitted to triexponential equations with terminal half-lives (t 1/1) of 23 and 22 h and area of 3.6 and 3.21/kg, respectively. Intravenous data predicted hepatic blood extraction ratios for the 2 subjects to be 0.06 and 0,07, respectively. Absolute bioavailability from oral solution (10 mg) was 59 and 34%, and from tablets (8 mg) 44 and 25%, respectively, indicating extensive gut first-pass metabolism. Mean t 1/2 from 7 oral fasting studies in 5 subjects was 28 h (19-43 h). Mean absorption lag time was 0.7 h (0.4-1.3 h), and mean peak time was 2.8 h (2-4 h). In 2 subjects, 6 mg solutions were given every 12 h for 9 doses; good correlation between single and multiple dose kinetics was found. Significant accumulation was demonstrated in simulation studies with frequent daily dosing. Estimated accumulation ratios vary from 4.1 to 9.4 (mean 6.5). The t 1/2 from urinary data (collected for 12 days) was consistent with plasma data. The above results suggest the need to reexamine the current practice of frequent daily dosing and the use of sustained or controlled release dosage forms of this drug. The possible cause of reduced plasma clearance of CPM in renal patients is discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7106172     DOI: 10.1007/BF00548406

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  INFLUENCE OF URINE PH AND FLOW RATE ON THE RENAL EXCRETION OF CHLORPHENIRAMINE IN MAN.

Authors:  A H BECKETT; G R WILKINSON
Journal:  J Pharm Pharmacol       Date:  1965-04       Impact factor: 3.765

2.  Simplified gas chromatographic method for the determination of chlorpheniramine in serum.

Authors:  J W Barnhart; J D Johnson
Journal:  Anal Chem       Date:  1977-06       Impact factor: 6.986

3.  Degree and duration of skin test suppression and side effects with antihistamines. A double blind controlled study with five antihistamines.

Authors:  T J Cook; D M MacQueen; H J Wittig; J I Thornby; R L Lantos; C M Virtue
Journal:  J Allergy Clin Immunol       Date:  1973-02       Impact factor: 10.793

4.  GLC determination of chlorpheniramine in human plasma.

Authors:  S Hanna; A Tang
Journal:  J Pharm Sci       Date:  1974-12       Impact factor: 3.534

5.  Rapid compartment- and model-independent estimation of times required to attain various fractions of steady-state plasma level during multiple dosing of drugs obeying superposition principle and having various absorption or infusion kinetics.

Authors:  W L Chiou
Journal:  J Pharm Sci       Date:  1979-12       Impact factor: 3.534

6.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

7.  Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve.

Authors:  W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

8.  Sensitive GLC-mass spectrometric determination of chlorpheniramine in serum.

Authors:  J A Thompson; F H Leffert
Journal:  J Pharm Sci       Date:  1980-06       Impact factor: 3.534

9.  Pharmocokinetics of hexobarbital in man after intravenous infusion.

Authors:  D D Breimer; C Honhoff; W Zilly; E Richter; J M van Rossum
Journal:  J Pharmacokinet Biopharm       Date:  1975-02

10.  Determination of nanogram amounts of aromatic compounds by spectrophotometry on thin-layer chromatograms.

Authors:  P Haefelfinger
Journal:  J Chromatogr       Date:  1976-09-15
View more
  19 in total

1.  Torsades de pointes tachycardia induced by common cold compound medication containing chlorpheniramine.

Authors:  Amir M Nia; Uwe Fuhr; Natig Gassanov; Erland Erdmann; Fikret Er
Journal:  Eur J Clin Pharmacol       Date:  2010-07-31       Impact factor: 2.953

Review 2.  The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II).

Authors:  W L Chiou
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

3.  Effect of cimetidine on the pharmacokinetics and pharmacodynamics of chlorpheniramine and diphenhydramine in rabbits.

Authors:  K J Simons; X Chen; T G Fraser; F E Simons
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

4.  Pharmacokinetics from a dynamical systems point of view.

Authors:  J M van Rossum; J E de Bie; G van Lingen; H W Teeuwen
Journal:  J Pharmacokinet Biopharm       Date:  1989-06

Review 5.  Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy.

Authors:  F E Simons; K J Simons
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

Review 6.  Optimum pharmacological management of chronic rhinitis.

Authors:  F E Simons; K J Simons
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

7.  The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine.

Authors:  Sally Usdin Yasuda; Peter Zannikos; Andrea E Young; Karen M Fried; Irving W Wainer; Raymond L Woosley
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines).

Authors:  D M Paton; D R Webster
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

Review 9.  Pharmacologic treatment of rhinitis.

Authors:  F E Simons; K J Simons
Journal:  Clin Rev Allergy       Date:  1984-08

Review 10.  H1-receptor antagonists. Comparative tolerability and safety.

Authors:  F E Simons
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.